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PURPOSE. Posterior capsule opacification (PCO) is a vision-impairing disease that occurs in
some adults and most children after cataract surgery. Contractile myofibroblasts contribute to
PCO by producing wrinkles in the lens capsule that scatter light. Myofibroblasts in the lens
originate from Myo/Nog cells named for their expression of the MyoD transcription factor and
bone morphogenetic protein inhibitor noggin. In this study we tested the effects of depleting
Myo/Nog cells on development of PCO.
METHODS. Myo/Nog cells were eliminated by injecting the G8 antibody conjugated to 3DNA
nanocarriers for the cytotoxin doxorubicin (G8:3DNA:Dox) during cataract surgery in rabbits.
The severity of PCO was scored by slit lamp analysis, gross and histologic observation, and
immunofluorescence localization of a-smooth muscle actin.
RESULTS. G8:3DNA:Dox specifically induced cell death in Myo/Nog cells in the lens. None of
the lenses administered G8:3DNA containing 9 to 36 lM doxorubicin developed greater than
trace levels of central PCO and few myofibroblasts were present on the capsule. Less than 9%
of these lenses exhibited greater than mild levels of peripheral PCO. Doxorubucin itself
reduced PCO; however, myofibroblasts and wrinkles were abundant in the lens, and off-target
effects were observed in the ciliary processes and cornea.
CONCLUSIONS. Myo/Nog cells are the primary source of myofibroblasts in the lens after cataract
surgery. Targeted depletion of Myo/Nog cells has potential for preventing PCO and preserving
vision.
Keywords: Myo/Nog, posterior capsule opacification, myofibroblasts
Cataracts are opacifications of the lens that may be presentat birth or develop with aging in response to prolonged
exposure to sunlight, smoking, diabetes, or surgery for other
ocular diseases.1 They are the leading cause of visual
impairment and blindness worldwide.2,3 The World Health
Organization estimates that by 2020, 32 million cataract
operations will be performed each year. Removal of cataract
tissue restores vision; however, 20% to 40% of adults and most
children develop a reopacification of the lens, called posterior
capsule opacification (PCO), within 3 years of surgery.4–9 The
incidence of PCO continues to rise as the patient ages, such
that everyone who undergoes cataract surgery is predicted to
require further treatment to improve vision.6,8,10,11
Most patients with PCO are treated with neodymium-doped
yttrium aluminum garnet laser to clear the lens. While this
procedure is effective for most patients, laser therapy is not
available worldwide, often has to be repeated, and is estimated
to cost health care providers hundreds of millions of dollars a
year.6,12 Some patients develop complications from laser
treatment, including retinal detachment and gliosis, macular
edema, and glaucoma that further compromise vision and
escalate health care costs.8,10–12 Currently, there is no method
for preventing PCO and eradication of the condition remains an
unmet goal in ophthalmology.
PCO results from abnormal cellular responses to cataract
surgery.8,13,14 In the regenerative form of PCO, epithelial cells
remaining in the lens form masses of differentiating cells called
Elschnig pearls and Soemmering’s rings.8,13,15 Both pearls and
rings may affect vision depending on their size and location
along the visual axis. Lens epithelial cells also may undergo an
epithelial to mesenchymal transition and populate the normally
cell-free posterior capsule in response to wounding.8,13,16 In
this process, called fibrotic PCO, an abnormal amount of
extracellular matrix is deposited on the capsule. A similar
phenomenon may occur on the anterior capsule (anterior
capsule opacification, ACO). One feature of fibrotic PCO and
ACO that significantly contributes to a decline in visual acuity is
wrinkling of the capsule by contractile myofibroblasts.13,16,17
Lens epithelial cells that have transitioned to a mesenchymal
phenotype synthesize the myofibroblast marker a-smooth
muscle actin (a-SMA).16,18–20 However, knockdown of a-SMA
in cultures of human lens cells does not inhibit matrix
contraction, suggesting that other muscle proteins such as
myosin may mediate contraction in this system.21
We discovered a distinct population of myogenic cells
within the lens, called Myo/Nog cells, named for their
expression of the skeletal muscle–specific transcription factor
MyoD and the bone morphogenetic protein (BMP) inhibitor
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noggin.22–24 Myo/Nog cells were first identified in the
blastocyst of the chick embryo.22,25,26 During gastrulation,
they are distributed in low numbers throughout the embryo,
including the eyes.24,27,28 Stable transcription of both genes,
regardless of their environment, ensures that Myo/Nog cells
remain committed to the skeletal muscle lineage and serve as
essential regulators of BMP signaling.24,27–29 Elimination of
Myo/Nog cells in the blastocyst results in hyperactive BMP
signaling and severe malformations, including eye defects
ranging from anophthalmia to lens dysgenesis and overgrowth
of the retina.24,28,30
Myo/Nog cells also react to wounding in the embryo and
adult.30–37 Within 24 hours of epidermal abrasion, Myo/Nog
cells increase in number and populate the wound.38 In the
retina, the Myo/Nog population expands in response to
hypoxia and damaging levels of light.34,35 Depletion of Myo/
Nog cells in the mouse model of retinopathy of prematurity
results in an increase in photoreceptor cell death, and their
addition to the vitreous following light damage reduces cell
death and improves visual performance.34,35
While Myo/Nog cells are neuroprotective in the retina, their
wound-healing response in the lens may be detrimental to
vision. In the human lens, Myo/Nog cells surround wounds,
synthesize a-SMA and skeletal muscle proteins, and overlie
wrinkles in the capsule.32,33 Depletion of Myo/Nog cells with
the targeting G8 monoclonal antibody (mAb) bound to
complement or conjugated to two-layered 3DNA nanocarriers
intercalated with the cytotoxin doxorubicin (G8:3DNA:Dox)
prevents the emergence of myofibroblasts in response to
wounding in explant cultures of chick embryo and human
anterior lens tissue.32,33,37
The behavior of Myo/Nog cells in the lens in vivo has been
studied in rabbits. Within 24 hours of cataract surgery, their
number was significantly elevated in the lens, ciliary body, and
cornea.36 Myo/Nog cells also have been found on the zonules
of Zinn, apparently migrating between the ciliary processes
and lens36 (Gerhart JV, et al. IOVS 2017;58:ARVO E-Abstract
3635). One month after surgery, Myo/Nog cells are present on
the internal and external surfaces of the posterior capsule;
express a-SMA, MyoD, and striated muscle myosin; and overlay
wrinkles in the capsule.36 In this report, we describe the effect
of depleting Myo/Nog cells on the development of PCO
following cataract surgery in rabbits.
METHODS
Cataract Surgery
Cataract surgery was performed on New Zealand white, female
rabbits weighing between 2.8 and 3.2 kg as described
previously.38–40 Details of surgery are provided in the
Supplementary Material. All procedures adhered to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Drug Treatment
A total of 900 lL balanced salt solution (BSS) or drugs diluted in
BSS was injected behind and in front of the intraocular lens
(IOL). Drug treatments consisted of purified G8 IgM mAb
conjugated to two-layered 3DNA nanocarriers (Genisphere,
LLC, Hatfield, PA, USA) (G8:3DNA), doxorubicin (Dox) (Sigma-
Aldrich, St. Louis, MO, USA), 3DNA intercalated with doxoru-
bicin (3DNA:Dox), G8:3DNA intercalated with Dox
(G8:3DNA:Dox), and 3DNA:Dox. Synthesis of 3DNA, conjuga-
tion to the G8 mAb, maintenance of functional binding activity,
and internalization has been described previously.33 The
amounts of G8 mAb, 3DNA, and Dox for each dose are listed
in Table 1.
Gross and Histologic Analyses of the Anterior
Segment
Eyes were examined grossly the first 2 days after surgery for
untoward effects, including inflammation, bleeding, and
corneal edema. The number of eyes obtained at 1, 2, and 28
days is indicated in Table 1. Globes were bisected coronally just
anteriorly to the equator. Gross examination and photographs
from the posterior aspect (Miyake-Apple view) were per-
formed to score (1) central PCO (3 mm behind the optic), (2)
peripheral PCO (extending from the optic-haptic junction
posteriorly), (3) ACO, (4) intensity and area of Soemmering’s
rings, and (5) IOL decentration and fixation.41,42 Capsular bags
were observed for epithelial outgrowth, fibrosis, capsular
wrinkling, Elschnig pearls, and fibrin deposits. Tissue was
embedded in paraffin, sectioned at 10 lm, and stained with
hematoxylin-eosin (H&E). Five sections from each eye were
evaluated for the extent of PCO and ACO, noting the presence
TABLE 1. Doses of G8 mAb, 3DNA, and Doxorubicin Injected Into the Lens and Number of Eyes Evaluated at 1, 2, and 28 Days Following Cataract
Surgery
G8 mAb, lg/mL 3DNA, lg/mL Dox, lM
No. Eyes
Day 1 Day 2 Day 28
BSS 0 0 0 2 2 15
G8:3DNA 152 70 0 1 0 6
3DNA:Dox 0 70 36 1 0 6
G8:3DNA:Dox 1.52 0.7 0.36 1 0 5
7.6 3.5 1.8 1 0 6
15.2 7 3.6 0 0 3
38 17.5 9 0 2 5
76 35 18 0 2 5
152 70 36 2 2 12
Dox 0 0 9 0 2 5
0 0 18 0 2 5
0 0 36 2 2 8
Eyes were injected with BSS or drugs after insertion of the IOL and before suturing. Eyes were evaluated by gross observation and histologically
1, 2, or 28 days postoperatively. Slit lamp examinations were performed on day 28.
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of proliferative cortical material, pearls and fibrous metaplasia,
openness of the trabecular meshwork, and morphology of the
ciliary body, cornea, and peripheral retina.
Evaluation of the Anterior Segment by Slit Lamp
Examination
Slit lamp examinations were performed weekly as described
previously.41,43 A scoring system of 0 (none observed), 1
(trace), 2 (mild), 3 (moderate), and 4 (severe) was used to
evaluate the anterior segments for (1) conjunctival injection
(redness) and discharge, (2) appearance of the limbal and iris
vasculatures, (3) corneal opacity/edema, (4) cellularity and
flare of the aqueous humor, (5) IOL centration, (6) posterior
synechia (adhesion of the iris to the anterior lens), (7)
inflammatory deposits, (8) ACO (area of the anterior capsule
in front of the anterior optic surface of the intraocular lens),
and (9) PCO (area of the posterior capsule behind the IOL).
Retroillumination images with the pupil fully dilated were
obtained for documentation of lens opacification and fibrosis.
Immunofluorescence Localization
Paraffin-embedded tissue sections of the anterior segment were
labeled with fluorescent antibodies as described previous-
ly.22,24,29 Sections were incubated with the G8 IgM mouse
mAb29 or G8 and an mAb to a-SMA directly conjugated with
fluorescein (Sigma-Aldrich). G8 was visualized with affinity-
purified, F(ab’)2 goat anti-mouse IgM l chain conjugated with
rhodamine (Jackson ImmunoResearch, West Grove, PA, USA).
Nuclei were labeled with Hoechst dye. Background fluores-
cence was assessed by incubating tissue sections with
secondary antibodies alone. Sections also were colabeled with
G8 and fluorescent terminal deoxynucleotidyl transferase–
dUTP nick-end labeling (TUNEL) reagents (Roche Diagnostics,
Mannheim, Germany) to detect cell death.30,32
Antibody labeling was analyzed with the Nikon Eclipse
E800 epifluorescence microscope (Nikon Instruments Inc.,
Melville, NY, USA) equipped with the Evolution QE Optronics
video camera and Image Pro Plus image analysis software
program (Media Cybernetics, Rockville, MD, USA). Figures
were annotated and adjusted for brightness and contrast with
Adobe Photoshop CC 2014 (Adobe Inc., San Jose, CA, USA).
Observational and Statistical Analyses
All analyses were performed while blinded to treatment.
Treatment groups were analyzed for differences in means by
analysis of variance. The Tukey’s test was used for pairwise
comparisons. Treatment groups failing to exhibit normality
with the Shapiro-Wilk test were analyzed by the Kruskall-
Wallace test followed by pairwise comparisons with the
Dunn’s test. Significant differences/P values were calculated
with a 95% confidence interval.
RESULTS
Effects of Drug Treatment on the Anterior Segment
24 to 48 Hours After Cataract Surgery
Eyes either appeared normal or exhibited mild corneal edema
located superiorly within the incision site on the first and
second day after surgery (Fig. 1). Both eyes that received 36 lM
Dox and one eye administered 18 lM Dox showed signs of
corneal edema and attenuation of the endothelium (Fig. 1).
No cell death was revealed with TUNEL staining in lenses
administered BSS, 36 lM Dox, or 3DNA:Dox the day after
surgery, whereas all G8þ cells were TUNELþwith the highest
dose of G8:3DNA:Dox 24 hours after surgery (not shown).
The results of TUNEL staining 2 days after surgery are
displayed in Figure 1 and Table 2. Fewer G8þ/TUNEL cells
were present in lenses injected with G8:3DNA:Dox than BSS,
reaching significance with the 18-lM dose. No G8þ/TUNELþ
cells were observed in BSS-treated lens. G8þ cells were dying
in lenses administered either G8:3DNA:Dox or Dox. The
number of G8þ/TUNELþ cells was significantly lower in
lenses treated with 36 lm than 18 lm G8:3DNA:Dox, possibly
reflecting a loss of dead cells between 24 and 48 hours of
treatment. Lenses with all three doses of Dox had significantly
more G8/TUNELþ cells than those with the highest dose of
G8:3DNA:Dox.
In the ciliary processes, the number of G8þ/TUNEL cells
was similar in all treatment groups (Table 2). No dying G8þ
cells were observed in this structure after administration of
G8:3DNA:Dox and few were dying in response to Dox.
However, significantly more G8/TUNELþ cells were present
in the ciliary processes with the two highest doses of Dox than
those administered any dose of G8:3DNA:Dox (Fig. 1; Table 2).
No G8þ cells appeared to be dying in the cornea following
treatment with BSS or any dose of G8:3DNA:Dox (Fig. 1; Table
2). Significantly more G8þ/TUNELþ cells were observed with
the highest dose of Dox than BSS and all three doses of
G8:3DNA:Dox (Table 2). The number of G8/TUNELþ cells
also was significantly higher in the cornea of eyes administered
the highest dose of Dox than the two highest doses of
G8:3DNA:Dox.
These results demonstrate that G8:3DNA:Dox induces cell
death in Myo/Nog cells of the lens. Very few G8þ/TUNELcells
remained in the lens 2 days following drug treatment. The lack
of significant differences between the number of G8/TUNELþ
cells in the lens in response to BSS versus G8:3DNA:Dox
suggests that the drug specifically targets Myo/Nog cells. By
contrast, Dox kills Myo/Nog and lens epithelial cells and has
off-target effects in the ciliary body and cornea.
Effect of Drug Treatment on the Development of
PCO
PCO was not visible by slit lamp examination 1 week
postoperatively. Trace levels of PCO (scores of 0.5–1)
beginning at the optic-haptic junction were visible in some
lenses in all treatment groups 2 weeks after surgery except
those administered 3.6 lM G8:3DNA:Dox (Supplementary
Table S1). By week 3, PCO had progressed from trace to mild in
all treatment groups except lenses injected with 3.6 to 36 lM
G8:3DNA:Dox, 9 to 36 lM Dox, and 36 lM 3DNA:Dox
(Supplementary Table S1).
Photographs of slit lamp examinations at week 4 are
displayed in Supplementary Fig. S1. Whereas 80% to 100% of
lenses injected with BSS and G8:3DNA had developed mild to
severe PCO, only 20% to 33% of lenses given the two highest
doses of G8:3DNA:Dox had greater than trace levels of PCO on
week 4 (Table 3). No PCO was observed in 20% to 40% of the
lenses treated with the two highest concentrations of
G8:3DNA:Dox and Dox. The percentage of lenses with greater
than trace levels of PCO also was reduced after treatment with
comparable doses of Dox or 3DNA:Dox (17%–40%). None of
the lenses treated with G8:3DNA:Dox, Dox, or 3DNA:Dox had
severe PCO. A downward trend in the mean PCO scores was
observed from BSS and G8:3DNA to the three highest doses of
G8:3DNA:Dox, Dox, and 3DNA:Dox, although significant
differences were not found between the treatment groups
(Supplementary Fig. S2A).
The effect of drug treatment on central and peripheral PCO
was evaluated on week 4 by gross observation (Table 3).
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Whereas 33% to 53% of lenses treated with BSS or G8:3DNA
had mild to severe central PCO, no central PCO was found in
40% to 63% of lenses treated with the two highest doses of
G8:3DNA:Dox. None of the lenses administered the three
highest doses of G8:3DNA:Dox, two highest doses of Dox, or
3DNA:Dox had developed greater than trace levels of central
PCO. The mean central PCO scores were higher for BSS- and
G8:3DNA-treated lenses than 3.6 to 36 lM G8:3DNA:Dox, 9 to
36 lM Dox, and 3DNA:Dox (Supplementary Fig. S2B). A
significantly higher PCO score was found for 1.8 lM
G8:3DNA:Dox than the two highest doses of this drug and
highest dose of Dox.
Whereas 83% to 100% of lenses treated with BSS, G8:3DNA,
and the three lowest doses of G8:3DNA:Dox had developed
mild to severe peripheral PCO, no peripheral PCO had
developed in 20% to 40% of lenses administered the two
highest doses of G8:3DNA:Dox and Dox, and 3DNA:Dox (Table
3). Only 16% to 20% and 25% to 40% of lenses treated with the
two highest concentrations of G8:3DNA:Dox and Dox,
respectively, had greater than trace levels of peripheral PCO.
None of the lenses administered 9 and 18 lM G8:3DNA:Dox,
or 18 lM Dox, had moderate to severe peripheral PCO. The
mean peripheral PCO scores of the three highest doses of
G8:3DNA:Dox and Dox were lower than the means of BSS,
G8:3DNA, and low doses of G8:3DNA:Dox (Supplementary
Fig. S2C). BSS-treated lenses had significantly greater peripheral
PCO than the two highest doses of G8:3DNA:Dox and highest
dose of Dox. Significant differences also were observed
between low doses of G8:3DNA:Dox and high doses of
G8:3DNA:Dox, Dox, and 3DNA:Dox.
These analyses demonstrated that G8:3DNA:Dox, Dox, and
3DNA:Dox prevent or reduce the severity of PCO as measured
by slit lamp analysis. Central PCO was inhibited to a greater
extent than peripheral PCO. However, in both areas of the
capsule, most lenses treated with the higher doses of
G8:3DNA:Dox and Dox had only trace or no PCO.
FIGURE 1. Effects of drug treatment 2 days after cataract surgery. Lenses were injected with BSS or 36 lM G8:3DNA:Dox or Dox during cataract
surgery. Two days later, tissue sections were stained with H&E (A–F) or double labeled with the G8 mAb (green) and TUNEL reagents (red) (G–O).
Overlap of red and green appears yellow in merged images. Nuclei were labeled with Hoechst dye (blue).White arrows¼G8þ/TUNELþcells; green
arrows¼ G8þ/TUNEL cells; red arrows¼ G8/TUNELþ cells. Bar: 270 lM in (A–C), 54 lM in (D–F), and 9 lM in (G–O). C, cornea; CP, ciliary
processes; I, iris.
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Effects of Drug Treatment on ACO and
Soemmering’s Ring Formation
ACO, when present, ranged from trace to mild by slit lamp
analysis (not shown). None of the lenses in any treatment
group had above trace levels of ACO when scored by gross
observation (Supplementary Fig. S3A). Significant differences
in ACO scores between treatment groups were not found,
although the mean ACO scores were lower for the two highest
doses of G8:3DNA:Dox and Dox than lower doses of both
drugs.
Soemmering’s rings were scored as the area covered by the
ring multiplied by the intensity of regenerative material. The
TABLE 3. Percentage of Lenses With PCO
TX, lM Dox
BSS
G8:3DNA:Dox Dox
3DNA:Dox
0 0 0.36 1.8 3.6 9 18 36 9 18 36 36
Slit lamp PCO, No. lenses 15 6 6 6 2 5 5 12 5 5 8 6
% with 0 0 0 0 0 0 0 40 25 0 20 37.5 16.7
% with 0.5–1 20 0 16.7 0 0 40 40 41.7 60 40 37.5 66.7
% with 1.5–2 46.7 66.7 33.3 50 50 60 20 8.3 20 40 25 16.7
% with 2.5–3 26.7 16.7 50 50 50 0 0 25 20 0 0 0
% with 3.5–4 7 16.7 0 0 0 0 0 0 0 0 0 0
Central PCO, No. lenses 15 6 6 6 3 5 5 12 5 5 8 6
% with 0 0 0 0 0 0 0 60 41.7 0 40 62.5 33.3
% with 0.5–1 46.7 66.7 33.3 0 0 100 40 58.3 80 60 37.5 66.7
% with 1.5–2 20 0 16.7 16.7 33.3 0 0 0 20 0 0 0
% with 2.5–3 20 33.3 50 83.3 66.7 0 0 0 0 0 0 0
% with 3.5–4 13.3 0 0 0 0 0 0 0 0 0 0 0
Peripheral PCO, No. lenses 15 6 6 6 3 5 5 12 5 5 8 6
% with 0 0 0 0 0 0 0 40 33 0 20 37.5 33.3
% with 0.5–1 13.3 0 16.7 0 0 60 40 50 60 40 37.5 33.3
% with 1.5–2 33.3 66.7 16.7 0 66.7 40 20 8.3 20 40 25 16.7
% with 2.5–3 33.3 16.7 33.3 50 33.3 0 0 8.3 20 0 0 16.7
% with 3.5–4 20 16.7 33.3 50 0 0 0 0 0 0 0 0
PCO was scored by slit lamp examination. Central and peripheral PCO were scored by gross observation. The values are the percentage of total
lenses scored (No. of lenses) with PCO scores of 0¼ none; 0.5 to 1¼ trace; 1.5 to 2.0¼mild; 2.5 to 3.0¼moderate; and 3.5 to 4.0¼ severe. TX,
treatment.
TABLE 2. Cell Death in the Anterior Segment 2 Days Following Cataract Surgery
No.
Eyes
No.
Sect*
Lens† CP‡ Cornea§
G8þ/TUN G8þ/TUNþ G8/TUNþ G8þ/TUN G8þ/TUNþ G8/TUNþ G8þ/TUN G8þ/TUNþ G8/TUNþ
BSS 2 10 5 6 3 0 2 6 2 11 6 7 0.4 6 1 4 6 2 6 6 4 0 5 6 1
G8:3DNA:Dox
9 lM 2 8 1 6 1 4 6 5 2 6 3 8 6 3 0 1 6 2 6 6 4 0 3 6 4
18 lM 2 9 0.2 6 0.4 5 6 5 0.4 6 1 10 6 6 0 1 6 1 19 6 10 0 3 6 4
36 lM 2 8j j 1 6 2 2 6 4 0.3 6 1 7 6 4 0 0.2 6 1 6 6 3 0 2 6 4
Dox
9 lM 2 9 2 6 2 1 6 1 6 6 11 8 6 4 2 6 4 9 6 6¶ 12 6 8 3 6 9 42 6 39¶
18 lM 2 11 2 6 2 5 6 3 9 6 5 10 6 6 2 6 4 9 6 6 13 6 5 1 6 1 34 6 22
36 lM 2 7 3 6 4 5 6 4 13 6 8 10 6 8 3 6 5 14 6 2# 9 6 9 6 6 5 61 6 31#
* Tissue sections (Sect) were double labeled with the G8 mAb and TUNEL (TUN) reagents to detect cell death. The results are the mean 6
standard deviation of the number of cells in the lens, ciliary processes (CP), and cornea labeled for G8 only (G8þ/TUN), both G8 and TUNEL (G8þ/
TUNþ), or TUNEL only (G8/TUNþ).
† In the lens, the Kruskal-Wallace test showed significant differences among the groups of G8þ/TUNEL (P¼ 0.002), G8þ/TUNELþ (P¼ 0.002),
and G8/TUNELþ cells (P < 0.001). The Dunn’s test revealed significant differences between the numbers of G8þ/TUNEL and G8þ/TUNELþ cells
for BSS versus 18 lM G8:3DNA:Dox (P ¼ 0.016 and 0.002, respectively). Significant differences also were found between the numbers of G8/
TUNELþ cells: 36 lM G8:3DNA:Dox versus 9 lM (P¼0.012), 18 lM (P¼0.006), and 36 lM (P¼0.006) Dox. The Tukey’s test revealed a significant
difference between the number of G8þ/TUNELþ cells in lenses treated with 18 and 36 lm G8:3DNA:Dox (P ¼ 0.03).
‡ In the ciliary processes, the Kruskal-Wallace test showed significant differences among the groups of G8þ/TUNELþ (0.01) and G8/TUNELþ
cells (P < 0.001). No significant differences were found among the groups of G8þ/TUNNEL cells (P¼0.38) or between pairs of G8þ/TUNELþ cells
with the Dunn’s test. Significant differences were found between the numbers of G8/TUNELþ cells: 18 lM Dox versus 18 lM (P¼ 0.024) and 36
lM (P ¼ 0.009) G8:3DNA:Dox; 36 lM Dox versus 9 lM (P¼ 0.025), 18 lM (P¼ 0.014), and 36 lM (P¼ 0.006) G8:3DNA:Dox.
§ In the cornea, no significant difference in the groups of G8þ/TUNEL cells were found with the Kruskal-Wallace test (P¼ 0.079). Significant
differences were found among the groups of G8þ/TUNELþ and G8/TUNELþ cells (P < 0.001). The Dunn’s test revealed significant differences
between the numbers of G8þ/TUNELþ cells: 36 lM Dox versus BSS (P¼ 0.024) and 9 lM (P¼ 0.041), 18 lM (P¼ 0.031), and 36 lM (P¼ 0.041)
G8:3DNA:Dox. Significant differences also were found between G8/TUNELþ cells: 36 lM Dox versus 9 and 36 lM (P¼ 0.04) G8:3DNA:Dox.
j j One section without lens tissue.
¶ Values are from eight sections; one section with >25% G8/TUNELþ cells.
# Values are from four sections; three sections with >50% G8/TUNELþ cells.
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greatest reductions in the means from BSS, G8:3DNA, and low
doses of G8:3DNA:Dox occurred in lenses treated with the two
highest doses of G8:3DNA:Dox and Dox (Supplementary Fig.
S3B). Significant differences were found between BSS and 18
lM G8:3DNA:Dox and Dox, and 1.8 lM G8:3DNA:Dox and 18
lM G8:3DNA:Dox and Dox. These results demonstrated that
drug treatment reduces Soemmering’s rings.
Analyses of Myo/Nog Cells and Myofibroblasts 4
Weeks After Cataract Surgery
Tissue sections of the anterior segment were labeled with
antibodies to G8 and a-SMA 1 month after surgery to detect
myofibroblasts. In the lens, no significant differences were
found between the numbers of G8þ/a-SMA cells or G8/a-
SMAþ cells among the treatment groups (Table 4). However,
the numbers of G8þ/a-SMAþ cells did differ between
treatments. Significantly fewer G8þ/a-SMAþ cells were present
in lenses administered G8:3DNA:Dox than BSS or G8:3DNA. By
contrast, treatment with Dox or 3DNA:Dox did not signifi-
cantly reduce the number of myofibroblasts in the lens
compared to those injected with BSS or G8:3DNA.
G8þ/a-SMAþ myofibroblasts were abundant on the central
and peripheral posterior capsule (Fig. 2), in the equatorial
region, and occasionally on the anterior capsule in lenses
treated with BSS and G8:3DNA. Lenses administered Dox and
3DNA:Dox also contained myofibroblasts on the central and
peripheral regions of the posterior capsule and in anterior and
equatorial regions. G8þ/a-SMAþ and G8/a-SMAþ cells overlaid
wrinkles in the capsule that were more pronounced under
large aggregates of myofibroblasts than single or small clusters
of these cells (Fig. 2). Wrinkles were either absent or less
pronounced in lenses administered G8:3DNA:Dox than the
other treatment groups.
G8þ cells were present outside of the lens in all treatment
groups (Table 4). A small subpopulation of G8þ cells in the
ciliary processes were a-SMAþ except in eyes administered BSS
or 0.36, 1.8, 9, and 18 lM G8:3DNA:Dox. The number of G8þ/
a-SMAþ cells was significantly greater in 3DNA:Dox-treated
eyes than BSS, all doses of G8:3DNA:Dox, and two lowest
doses of Dox. G8þ/a-SMAþ cells were rarely found in the
cornea. No G8/a-SMAþ cells were detected in either the
ciliary processes or cornea outside of blood vessels in any of
the treatment groups.
In summary, double labeling with G8 and a-SMA antibodies
revealed that treatment with G8:3DNA:Dox significantly
reduced the number of myofibroblasts in the lens. The
targeting drug also reduced wrinkles in the lens capsule.
While Myo/Nog cells were present in the ciliary processes and
cornea, these structures contained few, if any, myofibroblasts
except in eyes treated with 3DNA:Dox.
Effects of Drug Treatment on Corneal Edema and
Cell Viability 4 Weeks After Cataract Surgery
Analyses of corneal edema by slit lamp examination on weeks 1
to 4 are displayed in Supplementary Text and Table S2. Gross
observation and histologic assessment on day 28 revealed that
the anterior chambers were clear and deep, irises and
peripheral retinas appeared normal, and the trabecular
meshworks were open in all eyes (Fig. 3). One rabbit exhibited
barely detectable corneal edema in the eye treated with 36 lM
G8:3DNA:Dox and a trace level of corneal edema in the eye
with the same dose of Dox.
The results of TUNEL staining in the lens 28 days after
surgery are displayed in Figure 3 and Table 5. Lenses treated
with the highest dose of G8:3DNA:Dox contained significantly
fewer G8þ/TUNEL cells than those administered BSS,
G8:3DNA, 3DNA:Dox, and 9 and 36 lM Dox. The population
of G8þ/TUNELþ cells was statistically similar among the
treatment groups. G8/TUNELþ cells were few in number in
BSS-, G8:3DNA-, and G8:3DNA:Dox-treated lenses, and signif-
icantly less abundant in the 18 lM G8:3DNA:Dox lenses than
those injected with the same dose of Dox or 3DNA:Dox.
In the ciliary processes, the numbers of G8þ/TUNEL and
G8þ/TUNELþ cells were statistically similar in all treatment
groups (Table 5). By contrast, the population of G8/TUNELþ
cells was significantly elevated in eyes administered BSS,
G8:3DNA, Dox (9 and 36 lM), and 3DNA:Dox compared to the
two highest doses of G8:3DNA:Dox. The cornea exhibited
significantly more of G8þ/TUNEL and G8/TUNELþ cells in
eyes treated with 36 lM Dox and 3DNA:Dox than the three
highest doses of G8:3DNA:Dox. Dying epithelial and stromal
cells were mostly concentrated in the peripheral cornea (Fig.
3).
In summary, fewer Myo/Nog cells were present in lenses
administered the highest dose of G8:3DNA:Dox than the other
treatment groups. Few cells were dying in the lens except in
those treated with the second highest dose of Dox and
3DNA:Dox. Treatment with Dox and 3DNA:Dox during
cataract surgery has lasting, toxic effects in the ciliary
processes and cornea.
DISCUSSION
The incidence of PCO has been reduced, but not eliminated,
by more extensive removal or repositioning of lens tissue
FIGURE 2. Myofibroblasts and capsular wrinkles in the lens 28 days
post cataract surgery. Tissue sections of lenses treated with BSS or 36
lM Dox and G8:3DNA:Dox were double labeled with antibodies to G8
(red) and a-SMA (green). Nuclei were labeled with Hoechst dye (blue).
Photographs were taken of the central region of posterior capsule
approximately 3 mm behind the optic and peripheral posterior capsule
extending from the optic-haptic junction posteriorly. Arrows illustrate
wrinkles in the posterior capsule. Scale bar: 27 lM.
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during surgery, advances in the composition and conformation
of IOLs, and posterior capsulorhexis.8,13,44–49 While certain
drugs may impede the initial response of cells to surgery, it is
uncertain whether they would continue to block development
of PCO that may arise months or years later.13,20,50–52
Cytotoxic drugs and chemicals that nonspecifically kill cells
at the time of surgery and extensive removal of lens epithelial
cells may cause the IOL to be more mobile, and drugs may
diffuse to surrounding ocular tissues and initiate an inflamma-
tory response to necrotic tissue.47,53–58 Currently, there is no
effective method for predicting who will develop PCO or
preventing its occurrence, and eradication of the disease
remains an unmet goal in ophthalmology. Prevention of PCO is
particularly important for insertion of shape-changing IOLs that
accommodate for distance because fibrosis and contractions
affect the flexibility of the lens capsule.59
In this study, we built upon our proof-of-concept experi-
ments demonstrating that G8:3DNA:Dox prevents the emer-
gence of myofibroblasts in explant cultures of human lens
tissue.33 The model we used to examine the drug’s effect on
development of PCO in vivo was the adult rabbit that develops
the disease within a month of cataract surgery, the approxi-
mate equivalent of 2 years in humans.60 The percentage of
adult rabbits that developed clinically significant PCO resem-
bles the high incidence of PCO in children who have
undergone cataract surgery.60 Thus, the rabbit is an aggressive
model of PCO formation that presents a significant challenge
for testing potential therapeutics.
Administration of G8:3DNA:Dox into the lens specifically
targeted Myo/Nog cells in the lens with minimal, if any, off-
target effects in the ciliary body and cornea during the first 48
hours following cataract surgery. By contrast, off-target effects
were observed 2 days after treatment with Dox that killed both
Myo/Nog and lens epithelial cells, as well as cells in the ciliary
processes and cornea. Dox also displayed adverse effects in the
cornea and ciliary processes 4 weeks after surgery, well after
the expected rate of drug elimination via the flow of aqueous
humor.61 Diffusion of Dox to surrounding tissues may lead to a
chronic, inflammatory wound environment in which cell death
continues in the absence of the original insult.
Targeted depletion of Myo/Nog cells in the lens with
G8:3DNA:Dox reduced PCO and Soemmering’s rings, myofi-
broblasts, and wrinkles in the lens capsule without apparent
off-target effects in other structures of the anterior segment 4
weeks after surgery. Doses of G8:3DNA:Dox containing 9 to 36
lM Dox prevented central PCO from developing above trace
levels. Fewer than 9% of lenses administered these doses of
G8:3DNA:Dox exhibited greater than mild levels of peripheral
FIGURE 3. Effects of drug treatment 4 weeks after cataract surgery. Lenses were injected with BSS, 36 lM G8:3DNA:Dox, 36 lM Dox (C, G, K, O, S),
or 9 lM Dox (D, L, P, T) during cataract surgery. Four weeks later, tissue sections were stained with H&E (A–H) or double labeled with the G8 mAb
(green) and TUNEL reagents (red) (I–T). Overlap of red and green appears yellow in merged images. Nuclei were labeled with Hoechst dye (blue).
Boxes in (E–H) are shown at high magnification in (Q–T). White arrows¼ G8þ/TUNELþ cells; green arrows¼ G8þ/TUNEL cells; red arrows¼
G8/TUNELþ cells. Bar: 540 lM in (A–D), 270 in (E–H), and 9 lM in (I–T). C, cornea; CP, ciliary processes; I, iris.
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PCO. Administration of the drug as a sustained delivery
formulation may reduce the incidence of PCO even further
and protect the lens from Myo/Nog cells that migrate on the
zonule fibers from the ciliary processes to the lens36 (Gerhart
JV, et al. IOVS 2017;58:ARVO E-Abstract 3635). The modularity
of the 3DNA platform, as well as the wide range of available
conjugation chemistries, allows for the direct attachment of a
variety of small drugs. Thus, additional cytotoxins conjugated
to G8:3DNA can be tested for their effects on PCO.
Injection of Dox and 3DNA:Dox into the lens illustrated that
indiscriminate killing of cells in the lens also reduces PCO. Dox
may decrease the number of lens epithelial and Myo/Nog cells
available to migrate onto the posterior capsule. It is also
possible that remaining Myo/Nog cells respond to cell death
induced by Dox in the equatorial region and differentiate into
syncytia of myofibroblasts that create a barrier to posterior
migration. Precedence for this interpretation comes from our
previous study demonstrating that Myo/Nog cells rapidly
migrate to a subpopulation of dying cells in the early embryo.30
Whereas treatment with G8:3DNA:Dox significantly re-
duced the population of myofibroblasts in the lens, no
difference in the number of these contractile cells was
observed between Dox- and BSS-treated lenses. Myofibroblasts
overlaid wrinkles in the lens capsule. Distortions in the central
region of the posterior capsule are expected to affect visual
acuity by diffracting light; however, contractions occurring in
the peripheral portion of the posterior capsule also may impact
the visual axis.
The value of drugs that target a specific population lies in
their reduced side effects, as illustrated with the depletion of
Myo/Nog cells in the lens. Injection of drugs into the lens
during cataract surgery would minimally increase time in the
operating room. However, the synthesis of conjugates that
specifically deliver a cytotoxin to a tissue, or in the case of the
lens, the progenitors of myofibroblasts, is a more complex,
time-consuming, and costly process than production of a
cytotoxin alone. The return on the investment of conjugate
synthesis and administration is a potential savings of hundreds
of millions of dollars spent each year to treat PCO and the side
effects of laser therapy, and most importantly, preservation of
vision.
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